Ignite Creation Date:
2024-05-05 @ 4:51 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00322452
Status:
COMPLETED
Last Update Posted:
2013-11-07
First Post:
2006-05-05
Brief Title:
First Line IRESSA Versus CarboplatinPaclitaxel in Asia
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Open Label Randomised Parallel Group Multicentre Ph III Study To Assess Efficacy Safety Tolerability Of Gefitinib IRESSA Versus CarboplatinPaclitaxel DC As 1st-Line Treatment In Selected Patients With Stage IIIB IV NSCLC In Asia
Status:
COMPLETED
Status Verified Date:
2013-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
IPASS
Brief Summary:
The purpose of this study is to compare gefitinib with carboplatin paclitaxel doublet chemotherapy given as first line treatment in terms of progression free survival in selected NSCLC patients with the objective of demonstrating non-inferiority
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Iressa Pan Asian Study IPASS | None | None | None |